Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy
Status: Enrolling
Updated:  7/18/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy
Status: Enrolling
Updated: 7/18/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/18/2017
Mayo Clinic
mi
from
Scottsdale, AZ
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/18/2017
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/18/2017
Massachusetts General Hospital
mi
from
Boston, MA
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/18/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/18/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/18/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/18/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/18/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/18/2017
Washington University
mi
from
Saint Louis, MO
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/18/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Hyperthermic Intraperitoneal Chemotherapy as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma: A Prospective, Phase II, Proof-of-concept Study
Status: Enrolling
Updated:  7/18/2017
Carolinas Medical Center
mi
from
Charlotte, NC
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Hyperthermic Intraperitoneal Chemotherapy as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma: A Prospective, Phase II, Proof-of-concept Study
Status: Enrolling
Updated: 7/18/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated:  7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated: 7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Communicating Objective Risk for Personalized Decision Making About Mammography
Communicating Objective Risk for Personalized Decision Making About Mammography
Status: Enrolling
Updated:  7/20/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Communicating Objective Risk for Personalized Decision Making About Mammography
Communicating Objective Risk for Personalized Decision Making About Mammography
Status: Enrolling
Updated: 7/20/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Women and Infants Hospital
mi
from
Providence, RI
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated:  7/24/2017
Augusta University Medical Center
mi
from
Augusta, GA
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status: Enrolling
Updated: 7/24/2017
Augusta University Medical Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated:  7/24/2017
Cancer Treatment Services Arizona
mi
from
Casa Grande, AZ
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated: 7/24/2017
Cancer Treatment Services Arizona
mi
from
Casa Grande, AZ
Click here to add this to my saved trials
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated:  7/24/2017
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated: 7/24/2017
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated:  7/24/2017
Diablo Valley Oncology Hematology
mi
from
Pleasant Hill, CA
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated: 7/24/2017
Diablo Valley Oncology Hematology
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated:  7/24/2017
Little Company of Mary Hospital
mi
from
Evergreen Park, IL
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated: 7/24/2017
Little Company of Mary Hospital
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated:  7/24/2017
Rockford Memorial Hospital
mi
from
Rockford, IL
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated: 7/24/2017
Rockford Memorial Hospital
mi
from
Rockford, IL
Click here to add this to my saved trials
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated:  7/24/2017
Exeter Hospital
mi
from
Exeter, NH
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated: 7/24/2017
Exeter Hospital
mi
from
Exeter, NH
Click here to add this to my saved trials
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated:  7/24/2017
Parkridge
mi
from
Chattanooga, TN
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer
Status: Enrolling
Updated: 7/24/2017
Parkridge
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated:  7/24/2017
Klein Buendel, Inc
mi
from
Golden, CO
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated: 7/24/2017
Klein Buendel, Inc
mi
from
Golden, CO
Click here to add this to my saved trials
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated:  7/24/2017
Cancer Council Victoria
mi
from
Melbourne,
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated: 7/24/2017
Cancer Council Victoria
mi
from
Melbourne,
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Florida Hospital Orlando
mi
from
Orlando, FL
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Phoebe Putney Memorial Hospital
mi
from
Albany, GA
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Phoebe Putney Memorial Hospital
mi
from
Albany, GA
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Queen's Medical Center
mi
from
Honolulu, HI
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Univ of Hawaii
mi
from
Honolulu, HI
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Univ of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Castle Medical Center
mi
from
Kailua, HI
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Castle Medical Center
mi
from
Kailua, HI
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Weiss Memorial Hospital
mi
from
Chicago, IL
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Weiss Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
St. Francis Hospital and Health Centers - Beech Grove Campus
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Elkhart Clinic, LLC
mi
from
Elkhart, IN
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated:  7/25/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Home-Based Programs for Improving Sleep in Cancer Survivors
A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances
Status: Enrolling
Updated: 7/25/2017
Michiana Hematology-Oncology
mi
from
Elkhart, IN
Click here to add this to my saved trials